News Releases

Pfenex Strain Engineering to Host "Strategies for Accelerating Preclinical Development of Vaccines and Therapeutic Proteins" Seminar on Aug. 20th in Boston

San Diego,  California (June 19, 2013) – Pfenex Strain Engineering announced today that it will host a half day seminar on August 20, 2013 entitled “Strategies for Accelerating Preclinical Development of Vaccines and Therapeutic Proteins,” at the Westin Boston Waterfront Hotel.  This half day seminar will feature presentations and case studies focusing on how early stage decisions in expression strategies affect development timelines with speakers including Mark Poznansky, MD, Ph.D., Director of the Vaccine & Immunotherapy Center at Massachusetts General Hospital, Kevin Killeen, Ph.D., Chief Scientific Officer at Matrivax Research and Development Corporation and Dominic Esposito, Ph.D.,  Director, Protein Expression Laboratory Advanced Technology Program at SAIC-Frederick, Inc.  

The final program agenda will be released soon. For more information on the event and to register please visit:
About Pfenex Strain Engineering:
Pfenex Strain Engineering leverages its cutting edge technology platform and provides strain engineering services for those companies developing therapeutics and vaccines, and for those researchers seeking reagents for research use. Pfenex Strain Engineering is a division of Pfenex Inc. Headquartered in San Diego, California; Pfenex is a biotechnology company leveraging the proprietary Pfēnex Expression Technology™ platform for the development of biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  For more information, please visit
Pfenex Inc. 
Cassidy Brady 
Senior Marketing Manager 
Tel: +1 858 344-7207

Subscribe to our Investor Alerts
* Required Fields